In a new observational analysis, Risedronate significantly reduced nonvertebral fra...( MINNEAPOLIS (September 22 2003) In a ...),Health

MINNEAPOLIS (September 22, 2003) In a new observational analysis presented at the 25th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR), osteoporosis patients taking risedronate (Actonel) had a 59 percent (p=0.04) lower risk of nonvertebral fracture than patients receiving alendronate (Fosamax) and a 75 percent (p<0.01) lower risk than patients receiving nasal calcitonin, at one year of treatment.

"Fracture reduction is the clinically relevant endpoint for evaluating osteoporosis therapies," said Nelson B. Watts, MD, presenting author and Director, University of Cincinnati Bone Health and Osteoporosis Center. "While only head-to-head clinical trials comparing fracture efficacy can confirm differences in efficacy between osteoporosis therapies, the results for risedronate in this analysis are consistent with the early fracture reduction that has been shown for this agent in clinical trials."

About the Analysis
The retrospective analysis was based on data from a large medical and pharmaceutical managed care claims database. A one-year analysis assessed nonvertebral fracture risk in 5,024 patients who began treatment with risedronate (5 mg daily or 30 mg weekly), alendronate (5/10 mg daily or 35/70 mg weekly) or nasal calcitonin (200 I.U. daily), between July 2000 and June 2001. Nonvertebral fractures were defined as osteoporotic fractures of the clavicle, upper arm, forearm, pelvis, hip and leg.

Patients in the analysis were age 45 and older (93 percent women, mean age 69 years). Patients with prescriptions in the prior six months for a bisphosphonate, nasal calcitonin or raloxifene were excluded. All risk estimates were adjusted for age, sex, estrogen use, prior fragility fractures and a general morbidity indicator (number of concomitant medications). A six-month analysis was also done involving 7081 patients initiating therapy between July 2000 and December 2001. At six months risedronat
'"/>


31-Dec-2000

Page: 1 2 3 4 5
Related medicine news :

1. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue
2. Gastrointestinal disorders are associated significantly with sleepless nights
3. Landmark survey reveals asthma in children remains significantly out of control in the United States
4. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
5. Elderly cancer patients are significantly under-represented in cancer clinical trials
6. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
7. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...
8. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer
9. New data show SPIRIVA significantly reduces COPD exacerbations and related health resource burden
10. GSKS Requip(R) (ropinirole HCl) significantly reduces periodic leg movements in patients with RLS
11. Two landmark studies show Taxotere (R) significantly improves survival in men with prostate cancer